Tag: BB-025
Basking Biosciences announces positive topline phase-one data on BB-025 reversal agent
Basking Biosciences has announced positive topline data from its phase-one study of BB-025, an investigational, rapid-acting reversal agent designed to specifically bind to and...
Basking doses first patients in phase-one study of stroke drug reversal...
Basking Biosciences has announced that the first participants have been dosed in a phase-one clinical study of BB-025—a rapid-acting reversal agent designed to specifically...
